Bluebird bio, a gene therapy maker, has agreed to be sold to investors in a deal worth $29 million upfront. The company had struggled to generate profits from its treatments and ultimately ran out of time. This significant sale marks a disappointing end to the company’s efforts to develop life-changing medicines.
Source: https://endpts.com/bluebird-bio-to-sell-to-investment-funds-after-struggling-to-make-money-from-gene-therapies